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Abstract
Background: HIV-1 R5 viruses are characterized by a large phenotypic variation, that is reflected by the mode of coreceptor
use. The ability of R5 HIV-1 to infect target cells expressing chimeric receptors between CCR5 and CXCR4 (R5
broad viruses),
was shown to correlate with disease stage in HIV-1 infected adults. Here, we ask the question whether phenotypic variation
of R5 viruses could play a role also in mother-to-child transmission (MTCT) of HIV-1 and pediatric disease progression.
Methodology/Principal Findings: Viral isolates obtained from a total of 59 HIV-1 seropositive women (24 transmitting and
35 non transmitting) and 28 infected newborn children, were used to infect U87.CD4 cells expressing wild type or six
different CCR5/CXCR4 chimeric receptors. HIV-1 isolates obtained from newborn infants had predominantly R5
narrow
phenotype (n=20), but R5
broad and R5X4 viruses were also found in seven and one case, respectively. The presence of
R5
broad and R5X4 phenotypes correlated significantly with a severe decline of the CD4+ T cells (CDC stage 3) or death within
2 years of age. Forty-three percent of the maternal R5 isolates displayed an R5
broad phenotype, however, the presence of the
R5
broad virus was not predictive for MTCT of HIV-1. Of interest, while only 1 of 5 mothers with an R5X4 virus transmitted the
dualtropic virus, 5 of 6 mothers carrying R5
broad viruses transmitted viruses with a similar broad chimeric coreceptor usage.
Thus, the maternal R5
broad phenotype was largely preserved during transmission and could be predictive of the phenotype
of the newborn’s viral variant.
Conclusions/Significance: Our results show that R5
broad viruses are not hampered in transmission. When transmitted,
immunological failure occurs earlier than in children infected with HIV-1 of R5
narrow phenotype. We believe that this finding
is of utmost relevance for therapeutic interventions in pediatric HIV-1 infection.
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Introduction
Mother-to-child transmission (MTCT) of human immunodefi-
ciency virus type 1 (HIV-1) is the primary mode of infection in
children. In year 2007, an estimated 420.000 new infections
occurred in children aged less than 15 years, most living in Sub-
Saharan Africa [1].
Several maternal parameters, including advanced clinical stage,
low CD4+ T cell counts, high plasma viral load were associated
with an increased risk of MTCT of HIV-1 (reviewed in [2]). There
are controversial data concerning the role of viral phenotype in
transmission. Although viruses using CXCR4 as coreceptor (X4
phenotype) can be transmitted when present in the mother,
CCR5-using viruses (R5 phenotype) are the most frequently
detected in newborns [3,4].
Evolution of HIV-1 coreceptor use during disease progression
has been demonstrated in adults as well as children [5,6]. The
evolution usually involves change from CCR5 use (R5 phenotype)
to CXCR4 use alone (X4) or in combination with CCR5 (R5X4)
and/or other minor coreceptors (multitropic viruses). CXCR4-
using viruses can be isolated prior to or during progression to
AIDS, however only from about one-half of patients with overt
AIDS [7,8], thus suggesting that R5 viruses obtained during
clinical progression may differ in phenotypic characteristics from
those obtained during the early stages of infection.
Phenotypic variation characterizes R5 viruses, as demonstrated
by their varying capacity to infect macrophages [9,10,11,12] or
their differential susceptibility to inhibition by CC-chemokines
[6,13,14]. Studies on the entry of R5 viruses into cells expressing
CCR5/CXCR4 chimeric receptors [15,16] showed that the
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on the mode of CCR5 use. In particular, it has been shown that
during disease progression R5 viruses evolve to multiple chimeric
receptor usage (called R5
broad), which in turn correlated with
CD4+ T cell decline in the patient [15]. Evolution of the R5
broad
phenotype was associated with decreased sensitivity to inhibition
by the CC-chemokine RANTES [15]. The ability of a viral
isolates to use one or more chimeric receptors is most probably a
reflection of a more efficient usage of the CCR5 molecule, as
suggested by our previous results demonstrating a higher
infectivity of the wild-type CCR5 expressing cells with R5
broad
compared to R5
narrow isolates [15]. In this study we asked the
question whether phenotypic variation, implying different mode of
CCR5 use in pregnant women could play a role in MTCT of
HIV-1 and in turn, also in pediatric disease progression.
Materials and Methods
Patients and virus isolation
Our study population included a total of 59 HIV-1 seropositive
women (24 transmitting and 35 non transmitting) and 28 infected
children. Viral isolates from mother-child pairs were available in
21 cases. Additional seven children were included in the study, but
the maternal samples were not available. Samples from non
transmitting mothers and mother-child pairs were collected within
the framework of two separate cohort studies in Northern Italy.
One cohort consisted of 15 infected mother-child pairs and 17 non
transmitting mothers who took part in a HIV-1 MTCT
multicenter study from 1989 to 1994 [4,6,17,18]. The second
cohort consisted of 9 infected mother-child pairs and 18 non
transmitting mothers collected in the framework of MTCT
multicenter study beginning in 1986 [3,19]. All samples were
from Italian subjects and collected before the introduction of any
MTCT preventive antiretroviral therapy. In 14 out of 16 children
tested the infection was possibly acquired during the intrapartum
period, since negative results were obtained by polymerase chain
reaction (PCR) within the first week of life. Postnatal transmission
was excluded in all cases, as none of the children was breast-fed.
The Ethical Committee approved the use of samples according to
national laws (in 1986, 1991 and 2008). An informed oral consent
was obtained from the pregnant women and, in the case of the
children, from the parents.
The clinical stage of the women and their children (available for
21 transmitting and 24 non transmitting mothers and for 26 out of
28 children respectively), was defined according to the guidelines
of the Centers for Disease Control (CDC) [20,21]. Most of the
mothers were asymptomatic at the time of virus isolation, with the
exception of three mothers: one non transmitting (clinical stage B,
A206) and two transmitting mothers, one with moderate
symptoms (clinical stage B, A225) and one with AIDS (clinical
stage C, A130). CD4+ T cell counts were provided with the
samples in many cases (for 17 transmitting and 28 non
transmitting mothers) [3,17]. HIV-1 p24 antigenemia and plasma
viral load were available for a limited number of women (33 and
17 mothers, respectively) and thus, were not included in the study
analysis.
HIV-1 infection of the children was determined by virus
isolation and PCR [18,22]. Clinical and immunological data of the
children were obtained throughout follow-up, i.e. until death or for
at least 10 years (Table 1). Children were treated only with mono
or dual antiretroviral therapy (ART). Highly active ART
(HAART) was not administered to children in groups 1, 2 and
3, whereas children in group 4 were treated only after entering
CDC category 3 or C.
Virus isolation was performed from patient’s PBMCs as
previously described [18,22]. HIV-1 p24 antigen (Ag) positive
culture supernatants, collected during first or second culture
passage, were used to prepare virus stocks. Maternal viral isolates
were collected during pregnancy, at delivery or within 5 months
after delivery (Table 2). Virus was isolated from infected children
at an age range between birth and 9 months.
Infection of U87.CD4 cell lines expressing wild type and
CCR5/CXCR4 chimeric receptors
Virus stocks were used to infect human glioma U87.CD4 cells
stably expressing the wild type chemokine receptors CCR5 or
CXCR4, or the six CCR5/CXCR4 chimeric receptors as
previously described [6,16]. Chimeric receptors were obtained
by replacing, beginning from the N-terminal, successively larger
parts of CCR5 with corresponding parts of CXCR4 [23]. In the
resulting chimeras CXCR4 comprised gradually larger parts: the
N-terminal tail only (FC-1), including the first transmembrane
portion (FC-2), the first (FC-4b), second (FC-5 and FC-6) and third
(FC-7) extracellular loops (Figure 1). Parental U87.CD4 cells,
engineered to express CD4 but no chemokine receptor, were used
as negative control.
Cells were infected in duplicate with each virus stock containing
at least 2 ng/ml HIV-1 p24 Ag. The cultures were kept for 7 days
and inspection for syncytia formation was performed at days 1, 3
and 7. Supernatant was collected on day 1, after washing, and at
the last day of infection, and tested for the presence of p24 Ag by
an in-house ELISA assay [24] (www.aaltobioreagents.ie). Cultures
were only considered for evaluation if HIV-1 p24 value at day 1
was below the lower detection limit of the assay. Viral antigen
production was considered positive when the absorbance at day 7
exceeded 0.2 Optical Density (O.D.).
Viruses able to use only the wild type CCR5 as coreceptor were
defined as R5
narrow, whereas R5 viruses able to use the chimeric
receptors, FC-1, FC-2, and FC-4b singularly or in different
combinations were defined as R5
broad, according to the previously
published classification [15]. R5X4 viruses used the six chimeric
receptors in different combinations, and were not further
classified.
Statistical analysis
Correlation between R5 phenotype and immunological CDC
stage of infected children were analyzed by Pearson’s chi-square
test. Comparison of the frequencies of the wild type chemokine
receptor and chimeric receptor usage in the two groups of mothers
was done by Fisher’s Exact test and Pearson’s chi-square test. The
Mann-Whitney test and Pearson’s chi-square test were used to
compare the level of CD4+ T cell counts in the two groups of
mothers. Analysis of variance (ANOVA) was performed to
demonstrate the association between CD4+ T cell values and
viral phenotype. Pearson’s chi-square test was used to determine
the correlation between clinical stage and the transmission status
of mothers. Values below 0.05 were regarded as statistically
significant.
Results
HIV-1 with R5
broad phenotype can be transmitted
Virus isolates obtained close to birth from 28 newborns were
analyzed for phenotypic variability in a cell line expressing wild
type or chimeric chemokine receptors. CXCR4 using virus was
isolated from one newborn only, confirming previous observations
that CCR5 is preferentially used by HIV-1 early after infection
[3]. Twenty out of 27 children (74.07%) with an R5 virus carried a
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narrow), whereas
the remaining 7 children (25.93%) harboured virus with broad use
of chimeric receptors (R5
broad) (Table 1). These results indicate
that transmission of R5
broad virus occurred in a significant
proportion of children even if the majority of viruses replicating
at a time point close to infection are restricted to the use of wild
type CCR5.
The R5
broad phenotype is predictive of early
immunological failure in children
Clinical and immunological data obtained during follow-up
were available for 25 out of 27 children carrying an R5 virus close
to birth and for the one child with the R5X4 virus (Table 1). The
presence of viruses with R5
broad phenotype in the infected
newborns was accompanied by a faster progression to immuno-
Table 1. Clinical and viral characteristics of HIV-1 infected children
(a).
Category of progression Child code
Phenotype
(b) close
to birth Age at category diagnosed
(c)
Death Therapy
(d)
CDC 3 CDC B CDC C
GROUP 1
CDC 3 or early death ,12 mos B111p Broad (1) 4 4 - - 60
B117p Narrow (5) 4 - 4 11 -
B183 Narrow (1.5) - - - 3 -
B193 Broad (4) 6 6 12 28 12
B196 R5X4 (1) 6 6 34 44 9
B201 Narrow (2) 6 - 6 9 -
B204 Broad (0) 6 6 - 38 4
B224 Narrow (1) 6 8 44 - 8
B314 Broad (0.5) - - - 9 -
B380 Narrow (6) 9 9 15 - 4
GROUP 2
CDC3 13–24 mos B252 Broad (1) 14 - 14 30 14
B256 Narrow (1.5) 17 - 5 46 7
GROUP 3
CDC3 25–36 mos B32 Narrow (3) 28 28 - 96 28
B34p Broad (3) 28 9 - - 70
B130 Narrow (3) 30 1 38 47 22
B199 Narrow (2) 27 24 - 60 27
GROUP 4
CDC3 36–60 mos B3 Narrow (6) 65 65 - - 54
B115 Narrow (3) 58 58 - - 59
B136 Narrow (3) 60 - - - 64
B145 Narrow (1) 48 48 98 - 51
B255 Narrow (3.5) 46 - 12 - 12
GROUP 5
CDC3 .60 mos or never B31p Narrow (0) - - - - 114
B115p Narrow (2.5) - - - - 52
B190 Narrow (1) - - - - 77
B225 Narrow (1) - - - - 40
B306 Narrow (9) - 28 - - 72
GROUP 6
Lost at follow-up B107p Narrow (1) n.a. n.a. n.a. n.a. n.a.
B139p Broad (4) n.a. n.a. n.a. n.a. n.a.
(a)symbol - means that the event has not occurred. n.a.=not available. Mos means months of age. Age of appearance of the different conditions is always indicated in
months.
(b)Narrow and broad refer to viruses with R5 phenotype. Viruses able to exclusively use wild type CCR5 receptor are defined narrow, whereas those using chimeric
receptors besides the wild type CCR5 are defined broad. In parenthesis is indicated the age in months of the virus phenotype determination.
Statistical analysis: Influence of virus R5
broad phenotype on disease progression including children of group 1 and 2, or children of group 1, 2 and 3: p=0.0260 and
p=0.0218 (Pearson’s chi Square), respectively.
(c)Age of entry into clinical or immunological category. Categories are defined according to the Centers for Disease Controls [21]: CDC 3=severe immune suppression;
CDC B=moderate clinical manifestations; CDC C=severe clinical manifestations.
(d)Age of start of mono or dual antiretroviral therapy, not HAART.
doi:10.1371/journal.pone.0003292.t001
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decline of the CD4+ T cell counts as fast as within 2 or 3 years of
age or died within 1 year (groups 1, 2 and 3) carried R5
broad
viruses close to birth (p=0.026 or p=0.0218, Pearson’s chi-
square, including groups 1 and 2, or groups 1, 2 and 3,
respectively). Whereas none of the children, who were classified
as CDC category 3 after 36 months of age or did not enter this
category during the follow up (groups 4 or 5), had a virus with
R5
broad phenotype close to birth. The only child with a R5X4
virus showed also a fast decline of the CD4+ T cell count (classified
CDC 3 within 6 months of age) and died at 44 months.
Specifically, all but one R5
broad isolate of the newborns used FC-
4b either alone (n=2) or in combination with FC-2 (n=4),
whereas only one virus isolate used FC-1 and FC-2 (Table 2).
Maternal viral phenotype is predictive of the newborn’s
virus
With the aim to understand if selective processes operate during
transmission, and thus could be predictive for disease progression,
we compared the phenotype of the virus isolates available from 21
mothers close to delivery with that of their newborn child (Table 2).
All ten mothers harbouring an R5
narrow virus had children whose
virus displayed the same phenotype. Interestingly, the six mothers
carrying R5
broad viruses transmitted in all but one case a virus with
R5
broad phenotype (identical or similar to the mother’s virus); in
the exceptional mother-child pair, virus with R5
narrow phenotype
was present in the child. The five mothers with an R5X4 virus
Table 2. Comparison of viral phenotypes of 21 mother-child pairs.
Patient code
(a) Wild type
coreceptor use
Chimeric receptor use Patient code
(a) Wild type
coreceptor use
Chimeric receptor use
A107p (+1) R5 - A34p (+3) R5 FC 1-2-4b
B107p (+1) R5 - B34p (+3) R5 FC 4b
A115 (+3) R5 - A111p (+1) R5 FC 1-2
B115 (+3) R5 - B111p (+1) R5 FC 1-2
A115p (+2.5) R5 - A139p (+4) R5 FC 2
B115p (+2,5) R5 - B139p (+4) R5 FC 4b
A117p (+5) R5 - A145 (+1) R5 FC 2
B117p (+5) R5 - B145 (+1) R5 -
A130 (0) R5 - A252 (20.5) R5 FC 2
B130 (+3) R5 - B252 (+1) R5 FC 2-4b
A136 (+1) R5 - A314 (0) R5 FC 2-4b
B 136 (+3) R5 - B314 (+0.5) R5 FC 2-4b
A224 (0) R5 -
B224 (+1) R5 -
A225 (0) R5 - A31p (0) R5X4 FC 1-2-4b-5-6-7
B225 (+1) R5 - B31p (0) R5 -
A255 (+0.5) R5 - A183 (0) R5X4 FC 2-4b-5-6-7
B255 (+3.5) R5 - B183 (1.5) R5 -
A256 (+1.5) R5 - A193 (+4) R5X4 FC 4b-6-7
B256 (+1.5) R5 - B193 (+4) R5 FC 2-4b
A196 (0) R5X4 FC 4b-5-6-7
B196 (+1) R5X4 FC 4b-7
A204 (0) R5X4 FC 4b-7
B204 (0) R5 FC 2-4b
(a)Isolates from corresponding mother-child pairs are indicated by the same number preceded by a letter: A for mothers and B for children. Time of sampling is indicated
in parenthesis as months before (-), after (+) or within 1 week from (0) delivery/birth. Pairs were grouped according to the mother’s virus phenotype, i.e. first those
carrying an R5
narrow,t h a na nR 5
broad and last an R5X4 virus.
Samples were used to infect U87.CD4 cells expressing wild type CCR5 or CXCR4, or one of the chimeric receptors FC-1, FC-2, FC-4b, FC-5, FC-6 or FC-7. Experiments were
repeated twice. –, means no chimeric receptor is used.
doi:10.1371/journal.pone.0003292.t002
Figure 1. Schematic representation of the chemokine receptors
CCR5 and CXCR4 and the chimeric CCR5/CXCR4 receptors.
Chimeric receptors FC-1, FC-2, FC-4b, FC-5, FC-6 and FC-7 were
obtained by replacing successively larger parts of CCR5 with
corresponding regions of CXCR4.
doi:10.1371/journal.pone.0003292.g001
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broad and in another
two cases R5
narrow virus. Looking at the details, coreceptor use of
child’s virus was narrower than the corresponding mother’s virus
in 7 out of 11 cases, identical in two cases, and a more flexible use
of the CCR5 was observed in one child (pair 252). Thus, a virus
with R5
broad phenotype was transmitted from the majority of
mothers carrying such viruses (5 out of 6; 83.3%), indicating that
the maternal viral phenotype is generally preserved during
transmission and can possibly be predictive of the phenotype of
the newborn’s viral variant.
Maternal viral R5 phenotype is not predictive of
transmission
To identify factors predictive of transmission the viral
phenotype of 59 mothers (24 transmitting and 35 non transmit-
ting) was investigated. Transmitting mothers carried more often
viruses able to use both CCR5 and CXCR4 as coreceptors than
non transmitting mothers, 29% (7 out of 24) and 8% (3 out of 35),
respectively, but this difference did not reach statistical significance
(p=0.074, Fisher’s Exact Test) (Figure 2). No mother carried a
monotropic X4 virus.
The analysis of the chimeric receptor usage showed that the
frequency of the R5
narrow phenotype was similar between the two
groups of mothers, 53% in non transmitting and 65% in
transmitting mothers (17 out of 32 and 11 out of 17, respectively)
(Figure 2). Furthermore, among the R5
broad isolates (15 and 6 in
non transmitting and transmitting mothers, respectively), no
difference was observed in the use of FC-1 and FC-2 receptors
between the 2 groups of mothers, while viruses from non
transmitting mothers utilized FC-4b more frequently than viruses
from transmitting mothers (13 out of 15 vs. 2 out of 6, respectively)
with a trend towards significance (p=0.056, Perason’s chi-square
test). This suggests that R5
broad viruses from non transmitting
mothers can use CCR5 at least as flexibly as viruses from
transmitting mothers.
Analyses of other factors potentially correlated with risk of
transmission disclosed that the two groups of mothers transmitting
and non transmitting, could not be distinguished by the clinical
stage (p=n.s., Pearson’s chi-square test) and the CD4+ T cell
counts (mean 478 and 426 cells/mm
3; p=n.s., Mann-Whitney
test). Furthermore CD4+ T cell values of mothers carrying viruses
with R5
narrow or R5
broad phenotype did not differ (p=n.s.,
ANOVA), but were significantly different from those of mothers
carrying CXCR4 using viruses (p=0.0014, ANOVA). Thus the
clinical and the immunological stage of the mothers did not seem
to influence the risk of transmission in our cohort.
Discussion
Biological characteristics of HIV-1 that are critical for the risk of
MTCT continue to be subject to discussion. R5 is the
predominant virus phenotype early in HIV-1 infection, both in
adults and in children born to HIV-1-infected mothers. Since tools
to test the mode of CCR5 use [15,16] have been developed in the
past years, we asked the question whether flexible use of CCR5,
here dissected into narrow and broad phenotype, would influence
transmission of HIV-1 and pediatric disease progression. In the
present study the infected newborns harboured mostly viruses of
R5 phenotype, a significant proportion (25.9%) of these was able
to use chimeric receptors, suggesting that viral variants with a
more flexible and efficient use of CCR5 (the R5
broad phenotype)
can exist close to infection in the child.
Of utmost relevance are our data, which show that the R5
broad
phenotypedetectedinthenewbornshortlyafterbirthwaspredictive
of a fast and severe immunological failure. Thus, R5
broad viruses
seem to determine detrimental effects similar to those known for
CXCR4 using viruses. These data support the finding by Casper et
al, who suggested that the immunological deterioration in HIV-1
infected children precedes the viral phenotypic switch to CXCR4
usage [25]. We suggest that pre-existing R5
broad viruses may have
caused the worsening of the disease. Interestingly, in our study all
but one newborn’s R5
broad virus were capable of FC-4b usage,
which indeed was previously shown to be linked to evolution to
CXCR4use in adults [15]. Further studies with sequential follow up
samples from children will clarify if the association with CXCR4
switch occurs also in pediatric HIV-1 infection.
In neonates the memory CD4+ T cells, which express high
levels of CCR5, are 6–7 times less represented than the naı ¨ve
CD4+ cells [26]. The latter predominantly express CXCR4
[26,27,28,29], and are primarily infected by CXCR4 using viruses
[30]. It is likely, that the R5
broad compared to R5
narrow viruses may
infect CD4+ naı ¨ve cells in addition to memory cells despite the
limited expression of the CCR5 molecule, due to their more
efficient usage of the coreceptor [15]. Interestingly, Sleasman et al.
[27] described that although HIV-1 infected neonates in general
contained 10 to 100 fold greater number of infected CD4+
memory cells than naı ¨ve cells, those children who rapidly
progressed in the disease had high proviral load in the CD4+
naı ¨ve cells. Thus, infection of naı ¨ve cells by R5
broad viruses may
interfere with CD4+ T cells production, and thus account for the
rapid disease progression observed in children harbouring these
viruses. It remains to be solved why CXCR4 using viruses are not
preferentially maintained during transmission, despite the high
prevalence of CXCR4+ naı ¨ve cells in neonates.
The detailed analysis of the mother’s viruses in comparison to
those of the corresponding child allowed us once again to pinpoint
that the R5 phenotype, either narrow or broad, was usually
maintained during the transmission event. On the contrary, the
R5X4 phenotype was predominantly lost during transmission.
Specifically, mothers with an R5X4 virus transmitted virus with a
whole array of phenotypes, i.e. R5
narrow,R 5
broad or R5X4. These
data lend further support to the lack of restriction in transmission
of R5
broad viruses and favour the possibility that the maternal viral
R5 phenotype is predictive of the transmitted variant.
Figure 2. Distribution of the viral phenotype of transmitting
and non transmitting mothers. Distribution of R5 (black) vs. R5X4
(white) viruses within all virus phenotypes (n=59 viruses; p=n.s.,
Fisher’s Exact Test) and of R5
narrow (dark gray) vs. R5
broad (light gray)
within the R5 phenotype (n=49 viruses; p=n.s., Fisher’s Exact Test).
doi:10.1371/journal.pone.0003292.g002
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phenotypically highly heterogenous populations. Whether a
selective process or simply a random event governs transmission
remains, however, a topic of discussion. [17,31,32,33].
We showed that mothers harbouring R5
broad viruses were not at
higher risk of transmission and the presence of HIV-1 with R5
broad
phenotype was not predictive for MTCT of HIV-1. The use of
chimeric receptors suggests a more flexible usage of CCR5, which
in turn may indicate increased viral resistance to inhibition by CC-
chemokines. In this respect, the trend of the non transmitting
mothers to more often carry viruses with the specific usage of the
FC-4b chimeric receptor than transmitting mothers, is intriguing.
Recently, Meddows-Taylor et al. described that non transmitting
mothers have significantly higher levels of CCL3 in the plasma
than transmitting mothers [34]. It could be envisaged that high
levels of CCL3 may be needed to efficiently inhibit R5
broad viruses
and, as a consequence, to prevent MTCT of HIV-1. In this
respect, it will be relevant to compare the level of CC-chemokines
in mothers harbouring R5
broad and R5
narrow viruses as well as to
study if R5
broad viruses have a lower sensitivity to the new CCR5
inhibiting drugs than R5
narrow viruses.
In summary our data show that approximately one forth of the
newborn’s R5 viruses have the capacity to use CCR5/CXCR4
chimeric receptors indicating that phenotypes with increased
flexibility of co-receptor use are not hampered during transmis-
sion. Conversely these viral variants are significantly linked with
severe immunological failure within the first years of age of the
infected children. These data may have important implications for
timely and appropriate therapeutic choice in pediatric HIV-1
infection.
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